FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022

被引：60

作者：

Rizzo, Carla ^{[1
]}

Amata, Sara ^{[1
]}

Pibiri, Ivana ^{[1
]}

Pace, Andrea ^{[1
]}

Buscemi, Silvestre ^{[1
]}

Piccionello, Antonio Palumbo ^{[1
]}

机构：

[1] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol STEBICEF, Viale Sci,Ed 17, I-90128 Palermo, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 09期

关键词：

FDA-approved; fluorine; heterocycles; CRYSTALLINE FORMS; SYNTHETIC ROUTES; IMAGING AGENT; IN-VITRO; AMG; 510; INHIBITOR; DISCOVERY; POTENT; ACID; ANTIANDROGEN;

D O I：

10.3390/ijms24097728

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted.

引用

页数：36

共 140 条

[1] Apalutamide: First Global Approval [J].

Al-Salama, Zaina T. .

DRUGS, 2018, 78 (06) :699-705

[2] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[3] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[4] Sofosbuvir for the treatment of hepatitis C virus [J].

Asselah, Tarik .

EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (01) :121-130

[5] Chlorination at the 8-position of a functionalized quinolone and the synthesis of quinolone antibiotic ABT-492 [J].

Barnes, David M. ;

Christesen, Alan C. ;

Engstrom, Kenneth M. ;

Haight, Anthony R. ;

Hsu, Margaret C. ;

Lee, Elaine C. ;

Peterson, Matthew J. ;

Plata, Daniel J. ;

Raje, Prasad S. ;

Stoner, Eric J. ;

Tedrow, Jason S. ;

Wagaw, Seble .

ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2006, 10 (04) :803-807

[6]

Bell I.M., 2012, Piperidinone Carboxamide Azaindane Cgrp Receptor Antagonists, Patent No. [2012064910 A1, 2012064910, WO2012064910A1]

[7]

Belyk K.M., 2013, Process for Making CGRP Receptor Antagonists, Patent No. [WO2013138418, 2013138418]

[8] Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation [J].

Beuckmann, Carsten Theodor ;

Ueno, Takashi ;

Nakagawa, Makoto ;

Suzuki, Michiyuki ;

Akasofu, Shigeru .

SLEEP, 2019, 42 (06)

[9] In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist [J].

Beuckmann, Carsten Theodor ;

Suzuki, Michiyuki ;

Ueno, Takashi ;

Nagaoka, Kazuya ;

Arai, Tohru ;

Higashiyama, Hiroyuki .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 362 (02) :287-295

[10]

Bjornson K., 2014, Patent WO, Patent No. 2014008285

← 1 2 3 4 5 6 7 8 9 10 →